CAPLIN POINT LABORATORIES
|
CAPLIN POINT LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 49.57 | 39.56 | 32.03 | 28.42 | 23.34 |
| CEPS(Rs) | 55.60 | 46.88 | 38.12 | 32.61 | 26.44 |
| DPS(Rs) | 4.50 | 4.00 | 3.00 | 2.50 | 2.20 |
| Book NAV/Share(Rs) | 235.91 | 183.89 | 144.94 | 114.21 | 78.03 |
| Tax Rate(%) | 16.48 | 20.05 | 19.83 | 20.18 | 22.18 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 30.03 | 31.08 | 30.55 | 30.13 | 35.74 |
| EBIT Margin(%) | 30.83 | 30.45 | 29.70 | 31.25 | 35.06 |
| Pre Tax Margin(%) | 30.77 | 30.39 | 29.55 | 31.22 | 34.97 |
| PAT Margin (%) | 25.70 | 24.30 | 23.69 | 24.92 | 27.22 |
| Cash Profit Margin (%) | 28.77 | 27.99 | 27.17 | 28.58 | 30.83 |
| Performance Ratios | |||||
| ROA(%) | 19.29 | 19.94 | 20.20 | 23.02 | 28.41 |
| ROE(%) | 23.68 | 24.77 | 25.65 | 29.58 | 37.14 |
| ROCE(%) | 26.85 | 28.77 | 28.82 | 33.35 | 45.59 |
| Asset Turnover(x) | 0.75 | 0.82 | 0.85 | 0.92 | 1.04 |
| Sales/Fixed Asset(x) | 3.17 | 2.92 | 2.73 | 2.76 | 2.58 |
| Working Capital/Sales(x) | 1.14 | 1.16 | 1.22 | 1.27 | 1.59 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.32 | 0.34 | 0.37 | 0.36 | 0.39 |
| Receivable days | 88.48 | 85.74 | 87.41 | 82.19 | 80.37 |
| Inventory Days | 64.15 | 58.42 | 71.75 | 58.28 | 18.54 |
| Payable days | 88.14 | 80.02 | 59.05 | 55.04 | 97.76 |
| Valuation Parameters | |||||
| PER(x) | 12.04 | 17.19 | 12.62 | 9.93 | 17.24 |
| PCE(x) | 10.73 | 14.50 | 10.60 | 8.66 | 15.22 |
| Price/Book(x) | 2.53 | 3.70 | 2.79 | 2.47 | 5.16 |
| Yield(%) | 0.75 | 0.59 | 0.74 | 0.89 | 0.55 |
| EV/Net Sales(x) | 2.80 | 3.75 | 2.55 | 2.34 | 4.51 |
| EV/Core EBITDA(x) | 8.28 | 11.00 | 7.70 | 6.71 | 11.66 |
| EV/EBIT(x) | 9.10 | 12.33 | 8.60 | 7.50 | 12.87 |
| EV/CE(x) | 1.89 | 2.75 | 1.99 | 1.80 | 3.94 |
| M Cap / Sales | 3.09 | 4.06 | 2.88 | 2.47 | 4.69 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 15.54 | 19.61 | 22.95 | 33.07 | 20.16 |
| Core EBITDA Growth(%) | 14.68 | 23.07 | 16.85 | 20.14 | 20.63 |
| EBIT Growth(%) | 16.97 | 22.62 | 16.84 | 18.61 | 20.36 |
| PAT Growth(%) | 22.22 | 22.68 | 16.90 | 21.82 | 22.07 |
| EPS Growth(%) | 25.32 | 23.52 | 12.67 | 21.76 | 21.90 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | 0.01 | 0.04 | - |
| Current Ratio(x) | 5.80 | 6.25 | 7.10 | 5.70 | 5.73 |
| Quick Ratio(x) | 4.72 | 5.15 | 5.85 | 4.05 | 5.30 |
| Interest Cover(x) | 579.65 | 552.17 | 198.25 | 843.86 | 391.22 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.02 | - |
Compare Financial Ratios of peers of CAPLIN POINT LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CAPLIN POINT LABORATORIES | ₹10,111.8 Cr | -1.5% | -16.1% | 106.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
CAPLIN POINT LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CAPLIN POINT LABORATORIES | -1.5% |
-16.1% |
106.3% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
